SEARCH:   Advanced

Blood, 1 November 2005, Vol. 106, No. 9, pp. 2992-2994. Prepublished online as a Blood First Edition Paper on July 14, 2005; DOI 10.1182/blood-2005-06-2238. This Article Full Text Full Text (PDF) All Versions of this Article: 2005-06-2238v1 106/9/2992    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Braiteh, F. Articles by Kurzrock, R. Search for Related Content PubMed PubMed Citation Articles by Braiteh, F. Articles by Kurzrock, R. Related Collections Neoplasia Brief Reports Clinical Trials and Observations Related Article in Blood Online Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  CLINICAL TRIALS AND OBSERVATIONS Brief report Successful treatment of Erdheim-Chester disease, a non–Langerhans-cell histiocytosis, with interferon- Fadi Braiteh, Cynthia Boxrud, Bita Esmaeli, and Razelle Kurzrock From the Phase I Program, Division of Cancer Medicine and the University of Texas Graduate School of Biomedical Sciences at Houston, Texas; the Section of Ophthalmology, Department of Plastic Surgery, M.D. Anderson Cancer Center, Houston, TX; and the Jules Stein Eye Institute, University of California, Los Angeles (UCLA) Santa Monica, CA. Erdheim-Chester disease is a rare non-Langerhans histiocytosis with multisystem involvement. To date, there is no standard treatment for this disorder, and more than half of the patients succumb within 3 years. Because interferon- promotes the terminal differentiation of histiocytes and dendritic cells, we hypothesized that this molecule would be a useful therapy for Erdheim-Chester disease. We therefore treated 3 patients with advanced disease with interferon- at a starting dose of 3 to 6 x 106 units, which was later reduced, during maintenance, to 1 x 106 units subcutaneous 3 times per week. Marked improvement was noted in all patients, with substantial retro-orbital disease regression within 1 month. Improvement in bone lesions, pain, diabetes insipidus, and other manifestations was gradual over many months. Responses were durable (3+ to 4.5+ years). Our observations suggest that this well-tolerated therapy has a significant effect on the course and outcome of Erdheim-Chester disease. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Article in Blood Online: Interferon-: still useful after all these years Eric J. Feldman Blood 2005 106: 2930-2931. [Full Text] [PDF] This article has been cited by other articles: J. A. Mills, R. G. Gonzalez, and R. Jaffe Case 25-2008 -- A 43-Year-Old Man with Fatigue and Lesions in the Pituitary and Cerebellum N. Engl. J. Med., August 14, 2008; 359(7): 736 - 747. [Full Text] [PDF] J. Haroche, Z. Amoura, F. Charlotte, J. Salvatierra, B. Wechsler, C. Graux, N. Brousse, and J.-C. Piette Imatinib mesylate for platelet-derived growth factor receptor-beta-positive Erdheim-Chester histiocytosis Blood, June 1, 2008; 111(11): 5413 - 5415. [Full Text] [PDF]

	Copyright © 2005 by American Society of Hematology         Online ISSN: 1528-0020